Press release
Pulmonary Arterial Hypertension Market Expands as Advanced Therapies and Drug Approvals Drive Global Growth | Top Companies are Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company
Pulmonary Arterial Hypertension Market
Pulmonary Arterial Hypertension (PAH) is a progressive disorder characterized by high blood pressure in the arteries of the lungs, leading to heart strain and potential failure. It is associated with genetic mutations, autoimmune diseases, and congenital heart conditions. Symptoms include shortness of breath, chest pain, and fatigue. The PAH market is expanding due to the need for targeted therapies and advanced diagnostics. Innovations in drug formulations and clinical trials are shaping future treatment landscapes.
📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Pulmonary Arterial Hypertension Market Landscape:- https://datamintelligence.com/download-sample/pulmonary-arterial-hypertension-market?Ranjith
☛ Pulmonary Arterial Hypertension Market Recent Developments 2025:
United States: Recent Industry Developments
✅ In September 2025, United Therapeutics Corporation announced positive Phase 3 results for Tyvaso DPI® (treprostinil inhalation powder) showing significant improvement in exercise capacity and pulmonary vascular resistance in PAH patients. The company is now seeking FDA approval for expanded indications.
✅ In August 2025, Johnson & Johnson (Janssen Pharmaceuticals) initiated a Phase 2 trial evaluating its oral prostacyclin receptor agonist for patients with WHO Group 1 PAH. The compound aims to improve endothelial function and delay disease progression.
✅ In July 2025, Gilead Sciences launched its digital health monitoring platform for patients receiving Letairis® (ambrisentan), integrating wearable-based cardiopulmonary analytics to support real-time therapy optimization.
✅ In May 2025, Merck & Co., Inc. announced the expansion of its cardiopulmonary R&D division in Boston, focusing on novel endothelin receptor antagonists (ERAs) and combination therapy trials for resistant PAH cases.
Japan: Recent Industry Developments
✅ In September 2025, Nippon Shinyaku Co., Ltd. launched a new oral selexipag formulation with enhanced bioavailability for the treatment of PAH, developed in collaboration with Actelion Pharmaceuticals (J&J).
✅ In August 2025, Ono Pharmaceutical Co., Ltd. partnered with Kyoto University Hospital to advance gene therapy research targeting BMPR2 mutations-a key genetic cause of heritable pulmonary arterial hypertension.
✅ In July 2025, Toray Industries, Inc. introduced a biodegradable nanoparticle drug delivery system designed to improve pulmonary absorption and reduce systemic side effects of PAH medications.
✅ In June 2025, Shionogi & Co., Ltd. began preclinical trials of a dual-pathway modulator that targets both nitric oxide and prostacyclin signaling to achieve enhanced pulmonary vasodilation.
☛ Pulmonary Arterial Hypertension Market Competitive Landscape:
Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation.
Research Methodology
We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.
📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/pulmonary-arterial-hypertension-market?Ranjith
☛ Segments Covered in the Pulmonary Arterial Hypertension Market:
By Drug Class: Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA), and Others
By Route of Administration: Inhalation, Injectable and Oral Administration
By Distribution channel: Hospital Pharmacy, Pharmacy stores, and Others
☛ This Report Includes:
✔ Comprehensive go-to-market strategies with actionable insights.
✔ Unbiased evaluation of overall market performance.
✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.
✔ Tailored regional and country-level reports with detailed localized analysis available on request.
✔ Identification of niche segments and high-growth regions presenting strong opportunities.
✔ Accurate regional forecasts using both top-down and bottom-up approaches.
📌 Get Corporate Access to Live Pulmonary Arterial Hypertension Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=pulmonary-arterial-hypertension-market?Ranjith
☛ Regional Analysis for Pulmonary Arterial Hypertension Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription
☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Market Expands as Advanced Therapies and Drug Approvals Drive Global Growth | Top Companies are Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company here
News-ID: 4250368 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Agentic AI Market to Reach US$ 98.26 Billion by 2033, Growing at 46.9% CAGR with …
The Agentic AI Market reached US$ 4.54 billion in 2025 and is expected to grow to around US$ 98.26 billion by 2033, expanding with a CAGR of approximately 46.9 % from 2026 to 2033 as enterprises increasingly adopt autonomous AI agents that can make decisions and execute complex workflows without continuous human intervention.
Growth is supported by rising demand across key applications such as enterprise workflow automation, autonomous decision‐making, intelligent virtual…
Hypersonic Weapons Market 2026 | Defense R&D Investments Surge Globally: U.S., C …
Global Hypersonic Weapons Market reached US$ 7.1 billion in 2022 and is expected to reach US$ 16.6 billion by 2031, growing with a CAGR of 11.2% during the forecast period 2024-2031.
Hypersonic weapons are advanced missile systems capable of traveling at speeds greater than Mach 5, or five times the speed of sound. These weapons combine extreme speed, maneuverability, and precision, making them challenging to detect and intercept. They are designed…
AI in Healthcare Market to Reach US$ 305.96 Billion by 2033, Growing at 30.1% CA …
The AI in Healthcare Market reached US$ 27.64 billion in 2024 and is expected to grow to around US$ 305.96 billion by 2033, expanding at a CAGR of approximately 30.1 % from 2025 to 2033 as artificial intelligence technologies become integral to healthcare operations and clinical decision‐making globally.
Growth is supported by increasing demand across key applications such as clinical diagnostics and imaging, predictive analytics for patient monitoring, drug discovery and…
United States Roofing Insulation Adhesives Market Forecast 2024-2031: High-Perfo …
Roofing Insulation Adhesives Market is valued at a significant CAGR during the forecast period (2024-2031).
Roofing Insulation Adhesives Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
